HIV Prevention Research (HPR)
CDC, in partnership with the Botswana Ministry of Health, conducted the ground-breaking TDF2 study to determine if a daily oral dose of antiretroviral drugs could reduce the risk of HIV transmission among heterosexual men and women. Providing antiretroviral drugs to uninfected individuals prior to HIV exposure is called pre-exposure prophylaxis, or PrEP.
TDF2 study findings, announced in July 2011, provide the first evidence that PrEP can reduce risk of HIV infection among heterosexuals. CDC is assessing data from this Botswana-based study and other PrEP research to develop interim guidance for use of PrEP in heterosexual populations.
To learn more:
- Press Release: CDC Trial and Another Major Study Find PrEP Can Reduce Risk of HIV Infection among Heterosexuals (July 2011)
- Fact Sheet: TDF2 Study of PrEP among Heterosexual Men and Women in Botswana (July 2011)
- Interview with TDF2 Trial Participant
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333
TTY: (888) 232-6348
- Contact CDC–INFO